301 related articles for article (PubMed ID: 31494078)
41. The application of BH3 mimetics in myeloid leukemias.
Parry N; Wheadon H; Copland M
Cell Death Dis; 2021 Feb; 12(2):222. PubMed ID: 33637708
[TBL] [Abstract][Full Text] [Related]
42. Drugs targeting Bcl-2 family members as an emerging strategy in cancer.
Leber B; Geng F; Kale J; Andrews DW
Expert Rev Mol Med; 2010 Sep; 12():e28. PubMed ID: 20822554
[TBL] [Abstract][Full Text] [Related]
43. Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.
Goldsmith KC; Hogarty MD
Curr Opin Investig Drugs; 2009 Jun; 10(6):559-71. PubMed ID: 19513945
[TBL] [Abstract][Full Text] [Related]
44. Targeting the B-cell lymphoma 2 anti-apoptotic proteins for cervical cancer treatment.
Abdul Rahman SF; Xiang Lian BS; Mohana-Kumaran N
Future Oncol; 2020 Oct; 16(28):2235-2249. PubMed ID: 32715755
[TBL] [Abstract][Full Text] [Related]
45. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy.
Tomek M; Akiyama T; Dass CR
J Pharm Pharmacol; 2012 Dec; 64(12):1695-702. PubMed ID: 23146031
[TBL] [Abstract][Full Text] [Related]
46. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
[TBL] [Abstract][Full Text] [Related]
47. Bcl-2 inhibitors as anti-cancer therapeutics: The impact of and on calcium signaling.
Vervloessem T; Kerkhofs M; La Rovere RM; Sneyers F; Parys JB; Bultynck G
Cell Calcium; 2018 Mar; 70():102-116. PubMed ID: 28705421
[TBL] [Abstract][Full Text] [Related]
48. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.
Ye L; Yuan G; Xu F; Sun Y; Chen Z; Chen M; Li T; Sun P; Li S; Sun J
Tumour Biol; 2015 May; 36(5):3447-55. PubMed ID: 25542230
[TBL] [Abstract][Full Text] [Related]
49. Bcl-2 inhibitors: emerging drugs in cancer therapy.
Bodur C; Basaga H
Curr Med Chem; 2012; 19(12):1804-20. PubMed ID: 22414090
[TBL] [Abstract][Full Text] [Related]
50. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
51. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
Wang G; Zhan Y; Wang H; Li W
Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
[TBL] [Abstract][Full Text] [Related]
52. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
53. BCL-2 family antagonists for cancer therapy.
Lessene G; Czabotar PE; Colman PM
Nat Rev Drug Discov; 2008 Dec; 7(12):989-1000. PubMed ID: 19043450
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
55. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
Risberg K; Redalen KR; Sønstevold L; Bjørnetrø T; Sølvernes J; Ree AH
BMC Cancer; 2016 Jul; 16():531. PubMed ID: 27461218
[TBL] [Abstract][Full Text] [Related]
56. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
57. Proteins of the bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities.
Chan SL; Yu VC
Clin Exp Pharmacol Physiol; 2004 Mar; 31(3):119-28. PubMed ID: 15008953
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological inhibition of the Bcl-2 family of apoptosis regulators as cancer therapy.
Richardson A; Kaye SB
Curr Mol Pharmacol; 2008 Nov; 1(3):244-54. PubMed ID: 20021437
[TBL] [Abstract][Full Text] [Related]
59. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Tang Y; Zhang DY; Wu XM
Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
[TBL] [Abstract][Full Text] [Related]
60. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.
Vela L; Marzo I
Curr Opin Pharmacol; 2015 Aug; 23():74-81. PubMed ID: 26079328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
